Threshold Pharmaceuticals Inc. (NASDAQ:THLD)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a report released on Monday.

Separately, S&P Equity Research reduced their target price on Threshold Pharmaceuticals from $0.67 to $0.52 in a report on Friday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $7.26.

Analyst Recommendations for Threshold Pharmaceuticals (NASDAQ:THLD)

Threshold Pharmaceuticals (NASDAQ:THLD) traded down 1.11% during trading on Monday, reaching $0.67. The company’s stock had a trading volume of 1,535,319 shares. The company has a market cap of $47.91 million, a price-to-earnings ratio of 1.13 and a beta of 3.98. The stock’s 50 day moving average is $1.06 and its 200 day moving average is $0.62. Threshold Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $4.44.

Threshold Pharmaceuticals (NASDAQ:THLD) last released its earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, equities analysts expect that Threshold Pharmaceuticals will post ($0.38) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Oxford Asset Management increased its position in Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 178,602 shares during the last quarter. Paloma Partners Management Co purchased a new position in Threshold Pharmaceuticals during the second quarter valued at approximately $152,000. Renaissance Technologies LLC increased its position in Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 363,100 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock valued at $1,610,000 after buying an additional 500,000 shares during the last quarter. Finally, Deerfield Management Co. purchased a new position in Threshold Pharmaceuticals during the second quarter valued at approximately $1,641,000. Institutional investors and hedge funds own 28.22% of the company’s stock.

Threshold Pharmaceuticals Company Profile

Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

5 Day Chart for NASDAQ:THLD

Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.